Browse by author
Lookup NU author(s): Dr Richard Gilbertson, Dr Jackie Langdon, Roberto Hernan, Professor Steven CliffordORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Aberrant signalling via platelet derived growth factor receptors (PDGFRs) and the RAS/MAPK pathway has been implicated in the development of medulloblastoma, the most common malignant brain tumour in childhood. To determine whether genetic mechanisms play a role in the activation of PDGFR-RAS/MAPK signalling in medulloblastoma, we performed a direct sequence analysis of the established mutational "hotspots" of known targets of activating mutations within the pathway (PDGFRA, NRAS, KRAS, HRAS and BRAF) and PDFRFB, in a cohort of 28 primary tumours. A synonymous sequence variation in PDGFRA (CCG to CCA; PRO 567 PRO) was detected in two cases (∼7%), but not in 150 normal chromosomes assessed, suggesting that the PDGFRA locus may be associated with medulloblastoma development in certain cases. No evidence for oncogenic mutations affecting NRAS, KRAS, HRAS, BRAF or PDFRFB was found in any case. These data demonstrate that activating mutations in established mutational hotspots within the PDGFR-RAS/MAPK pathway are rare events in medulloblastoma development, and suggest that alternative mechanisms are responsible for RAS/MAPK pathway activation in this disease. © 2005 Elsevier Ltd. All rights reserved.
Author(s): Gilbertson R, Langdon J, Hollander A, Hernan R, Hogg T, Gajjar A, Fuller C, Clifford SC
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
Year: 2006
Volume: 42
Issue: 5
Pages: 646-649
Print publication date: 01/03/2006
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
URL: http://dx.doi.org/10.1016/j.ejca.2005.11.023
DOI: 10.1016/j.ejca.2005.11.023
PubMed id: 16434186
Altmetrics provided by Altmetric
